Jeff Knipstein: What’s next for Servier in IDH-mutant glioma
Jeff Knipstein, Medical Director of Servier Pharmaceuticals, shared a post on LinkedIn:
“For the past six years, the Glioblastoma Drug Development Summit has provided a space for those in our industry to share experiences, dive into learning processes and give an opportunity to collaborate with other experts in the field.
This year, I was able to share a summary of our research to-date in IDH-mutant glioma and provide a window into what’s next for Servier in this space.
Thank you to all who attended the session and to all those at the summit aiming to advance treatments for patients!”
Islam Hassan, Global Head of Development (Neuro-Oncology) at Servier Pharmaceuticals, shared this post, adding:
“At Servier, our unwavering dedication to IDH mutant glioma patients and the entire brain tumor community is evident in our relentless pursuit of groundbreaking scientific developments. We are committed to delivering new hope for our patients through innovation and unwavering commitment.
Also, We are fortunate to have such a talented and dedicated team. Jeff’s exceptional leadership in our vorasidenib combinations trials is just one example of the many reasons why we strive to make significant progress in the fight against IDH-mutant gliomas.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023